Taconic Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Taconic Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-30,000	Closed	-$1.65M	–	43
2025 Q2	$1.65M	Hold	30,000	–	–	0.13%	36
2025 Q1	$2.12M	Hold	30,000	–	–	0.15%	31
2024 Q4	$1.97M	Hold	30,000	–	–	0.14%	34
2024 Q3	$2.11M	Hold	30,000	–	–	0.17%	29
2024 Q2	$2.47M	Hold	30,000	–	–	0.19%	33
2024 Q1	$2.62M	Buy	30,000 +10,000	+50%	+$895K	0.24%	28
2023 Q4	$1.93M	Buy	+20,000	New	+$1.77M	0.13%	51

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Taconic Capital Advisors's BMRN Position: Q3 2025 in Review

Taconic Capital Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 30,000 shares — an estimated $1.65M sold.

Taconic Capital Advisors first reported a position in BMRN in Q4 2023 and held it in 7 quarters. The position peaked at $2.62M in Q1 2024. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

Taconic Capital Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Taconic Capital Advisors sold 30,000 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $1.65M.
Taconic Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 7 quarters.
Taconic Capital Advisors's BioMarin Pharmaceuticals position peaked at $2.62M in Q1 2024.
576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Taconic Capital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.